There is a limited number of clinical studies on interferon (IFN) levels in human brucellosis. The novel group of interferons, type III interferons, which consists of four IFN-λ (lambda) molecules called IFN-λ1 or interleukin-29 (IL-29), IFN-λ2 or IL-28A, IFN-λ3 or IL-28B, and IFN-λ4, is not fully known. This study is one of the first studies of IL-28A and IL-29 levels in brucellosis cases at the end of their treatment course. A total of 33 acute brucellosis patients were included in this study. We considered changes in the levels of IL-28A and IL-29 in cases with acute brucellosis before and after treatment with standard therapy that referred to the Ayatollah Rohani Hospital in Babol, northern Iran. Of 33 included patients, 22 (66.6%) were males, and 11 (33.4%) were females. The range of patients’ age was years. Serum IL-29 and IL-28A (acute form:  pg/mL and  pg/mL, respectively, and posttreatment:  pg/mL and  pg/mL, respectively) levels were elevated significantly in acute brucellosis than after treatment (). These findings indicate that considering biomarker levels in brucellosis patients may indicate the chronicity of infection. In conclusion, we suggest that IL-29 and IL-28A levels may be valuable biomarkers for follow-up patients with brucellosis.

中文翻译：

---

急性布鲁氏菌病患者治疗后 III 型干扰素下调

关于人类布鲁氏菌病干扰素 (IFN) 水平的临床研究数量有限。新型干扰素组，即 III 型干扰素，由四个 IFN- λ (λ) 分子组成，称为 IFN- λ 1 或白细胞介素 29 (IL-29)、IFN- λ 2 或 IL-28A、IFN- λ 3 或IL-28B 和 IFN- λ4、不完全清楚。这项研究是布鲁氏菌病病例治疗结束时 IL-28A 和 IL-29 水平的首批研究之一。本研究共纳入急性布鲁氏菌病患者 33 例。我们考虑了在伊朗北部巴博尔的 Ayatollah Rohani 医院接受标准疗法治疗前后急性布鲁氏菌病患者 IL-28A 和 IL-29 水平的变化。在纳入的 33 名患者中，22 名（66.6%）为男性，11 名（33.4%）为女性。患者年龄范围为年。血清 IL-29 和 IL-28A（急性形式： 皮克/毫升和 pg/mL，分别和后处理： 皮克/毫升和 pg/mL) 水平在急性布鲁氏菌病中显着高于治疗后 (）。这些发现表明，考虑布鲁氏菌病患者的生物标志物水平可能表明感染的慢性性。总之，我们认为 IL-29 和 IL-28A 水平可能是布鲁氏菌病随访患者的有价值的生物标志物。